The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Brandee McKoon tried the traditional diets to lose weight but didn’t have much luck. The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a global pharmaceutical firm, announced today the inauguration of the Lilly Seaport Innovation Center (LSC) in Boston's... Eli Lilly and ...

A Chinese start-up’s new artificial intelligence program took the top spot in Apple’s app store, threatening U.S. dominance ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/100.CtMQo59V.js ...